What FDA Warning Letters Say About Peptide Marketing: 2026 Update

Three FDA warning letters from 2026 show how the agency read peptide sales pages. FDA read the Research Use Only line together with the rest of each page. It cited item names, body and health claims, study claims, and goods sold as a set. Two letters were issued on March 31. The Wholesale Peptide letter came later, on June 17. Each letter states FDA's view of the facts it reviewed and asks the named firm to reply. Each letter names a firm, its items, and a review period.

Key Facts

• FDA reviewed the Prime Sciences website from January through March 2026 (U.S. Food and Drug Administration).
• FDA reviewed the Gram Peptides website from January through March 2026 (U.S. Food and Drug Administration).
• FDA reviewed the Wholesale Peptide website in May 2026 (U.S. Food and Drug Administration).
• Prime Sciences offered a reconstitution kit containing BAC water and a syringe (U.S. Food and Drug Administration).

TL;DR

• FDA asked Prime Sciences for a written response within fifteen working days of receipt (U.S. Food and Drug Administration).
• FDA asked Gram Peptides to detail each step taken to prevent recurrence (U.S. Food and Drug Administration).
• FDA verifies completed corrective actions before issuing a warning-letter close-out (U.S. Food and Drug Administration).
• Subsequent interaction between FDA and a warning-letter recipient may change the regulatory status of the issues raised (U.S. Food and Drug Administration).

Read the source type before the claim

A warning letter is an agency notice (U.S. Food and Drug Administration). It states what FDA saw, what the agency says the law requires, and what it asks the named firm to do. The recipient can reply. Later facts may change the record.

Describe a warning letter with the verbs FDA stated, FDA cited, or the letter says.

The three letters also use limits. They say the listed issues may not cover every issue. They ask for a written reply and records of fixes.

The cited allegation matrix

Read the linked letter before using a detail in a real review.

Prime Sciences: claims and combined goods

The Prime Sciences letter is dated March 31, 2026. FDA said it reviewed the site from January through March. It named six goods. The list included five peptide related items and BAC water. Warning letters that name peptide products are listed in the FDA warning letter tracker.

The Prime letter says the product labeling used lab research only and not for human, medical, or vet use text. FDA then cited other page text. The examples dealt with weight change, appetite, glucose, body processes, and diabetes or obesity framing. Some text drew on study or trial results.

FDA also cited a reconstitution kit. The agency said it held BAC water and a syringe (U.S. Food and Drug Administration). It was offered with peptide goods that FDA described as meant for injection. FDA treated that sales context as part of its intent analysis.

The letter states FDA's finding that the named goods were unapproved new drugs under the law it cites. It states that their entry into interstate trade broke the listed parts of the law. It asks the firm to reply with steps and records. FDA asked Prime Sciences for a written response within fifteen working days of receipt (U.S. Food and Drug Administration).

Gram Peptides: RUO text and page claims

The Gram Peptides letter is also dated March 31, 2026. FDA said it reviewed the site from January through March. It named Retatrutide, Tirzepatide, and Bacteriostatic Water for Injection.

The Gram letter says the product labeling used Research Use Only text. FDA cited other page text about appetite, glucose, body weight, insulin, lipids, and body processes. The agency said this text showed intent for human drug use.

The letter also looked at goods sold together. FDA said Bacteriostatic Water for Injection was sold alongside the named peptide goods (U.S. Food and Drug Administration). The agency used that fact in its view of how the water was meant to be used.

FDA stated that the three named goods were unapproved new drugs under the cited law. It asked the firm for a written reply. The letter also says its list may not include each issue that could exist. FDA asked Gram Peptides for a written response within fifteen working days of receipt (U.S. Food and Drug Administration).

FDA treated the RUO text as one fact among several in this review. The page claims and sales setting were part of the record the agency described.

Wholesale Peptide: a later letter with a different pattern

The Wholesale Peptide letter is dated June 17, 2026, a separate date from the two March 31 letters. FDA said the cited site review took place in May.

The letter named two goods, Prostamax and Gonadorelin (U.S. Food and Drug Administration). For Prostamax, FDA cited page text about the prostate, swelling, bladder control, urine signs, and tissue changes. For Gonadorelin, it cited text about body processes and cancer research.

The letter says FDA viewed the site text as proof of intended drug use. It states that the two goods were unapproved new drugs and that the sale described broke the cited law. It asks for a reply and steps meant to stop a repeat. FDA asked Wholesale Peptide for a written response within fifteen (15) business days of receipt (U.S. Food and Drug Administration). Tina Smith, FDA Director of the Office of Unapproved Drugs and Labeling Compliance, told Wholesale Peptide, “you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures”.

Footnote 1 in the Wholesale letter says the labels used Research Use Only and not for human consumption text. FDA said other product labeling, including the site, showed human drug intent. The letter names its own two items. Give each notice its own row and source.

What the three letters share

The Prime letter, Gram letter, and Wholesale letter each record research or nonhuman use labeling. In each case, FDA said other labeling or site evidence showed human drug intent. The exact label words and cited site facts differ, so each fact must stay with its source. See also Preclinical vs Human Evidence in Peptide Research: BPC-157.

All three letters name exact goods. They also name a review span or month. Keep the item, site, and time together in each summary.

Each letter cites health, disease, or body process language. Review science style language on a sales page as product copy. A claim may point from a paper to the item on sale.

Two letters add context from goods sold together. Prime cited a kit. Gram cited water for injection sold with peptide items. Wholesale uses a different claim pattern. It focuses on the words used for two named goods.

Each letter states FDA's legal view. Each also asks for a reply.

Review each new page on its own record

Review each peptide seller's page on its own words and flow.

Check each study cited on a sales page for its fit with the item on sale. FDA cited study framed copy as part of product page text.

The Prime, Gram, and Wholesale letters show that FDA read the research labels together with other facts in each cited record.

Ask qualified counsel for legal advice about a real set of facts.

Save a later response or action as a new primary source. Mark its status UNKNOWN until that source is checked.

Build a letter reading record

Start one row per letter. Save the page title, firm, date, reference number, office, review period, named goods, cited site text, agency finding, reply request, and access date.

Use two fields for each key point. The first is exact source text or a close note. The second is a plain summary. This makes it easier to see when a summary grows too strong.

Add a source type field. Set it to FDA warning letter. If a later source changes the status, add a new row and keep the old source type in place.

Add a limit field. Record the firm, item, site, and time period named in the letter.

Use an owner and next check date. FDA pages and other facts can change. Date each record when its sources are checked.

Turn the letters into a page audit

Review the full sales path. Start with the item name and page title. Read the short copy, long copy, image text, study blocks, FAQs, and buttons. Then check related goods and the cart.

Look for health issue names, symptom words, body outcomes, and claims about a person. Mark text about appetite, weight, glucose, organs, or body processes for review. Do the same for study claims placed by a buy button. Related guide: FTC Substantiation Standard for Health Claims.

Check goods sold as a set. Note kits, water, tools, and cross sells. Read each item together with the rest of what the site puts alongside it.

Check RUO text in place. Is it clear? Does the rest of the page match it? Does support copy point the other way? The Research Use Only guide gives the focused review for labels, pages, images, reviews, support, and conduct.

Set each issue to KEEP, NARROW, REMOVE, HOLD, or COUNSEL. Send legal and safety questions to a fact based expert review.

Use careful editorial language

Write that FDA cited site text. Write that the letter states an agency finding. Name the firm, date, item, and page context.

Write FDA stated when the source is a warning letter. Write a court ruled only when a court source says so.

Keep each fact with its own letter. Prime has a kit example. Gram has an injection water example. Wholesale has the prostate and Gonadorelin copy. Keep each point with its own link.

Cite each letter with its exact date. Two letters share one issue date. The third came more than two months later. The dates help a reader check the right record.

Frequently Asked Questions

What dates were the three letters issued?

Prime Sciences and Gram Peptides were dated March 31, 2026. Wholesale Peptide was dated June 17, 2026, after a May site review.

What kind of document is a warning letter?

A warning letter is an FDA notice that states the agency's findings and asks the named firm to reply.

Did FDA ignore Research Use Only text?

The Prime, Gram, and Wholesale letters all note research or nonhuman use text. FDA then cited other labeling, site claims, or sales facts. The exact wording and facts differ across the three letters. For a closer look, read What Actually Happens If You Sell Peptides Wrong.

What does a study link do for product copy?

The page may imply that the item on sale has the result in the paper. Review the source, item, words, and page setting together.

How can a kit or related item affect the message?

FDA cited a kit in the Prime letter and water for injection sold with peptide goods in the Gram letter.

What products do the letters address?

Prime Sciences: Cagrilintide, GLP1-R, GLP1-S, GLP1-T, Mazdutide, and BAC water. Gram Peptides: Retatrutide, Tirzepatide, and Bacteriostatic Water for Injection. Wholesale Peptide: Prostamax and Gonadorelin.

What should happen if a later response is found?

Save it as a new source. Check who issued it and what it says, and keep it separate from the FDA view recorded in the original warning letter.

What response deadline did Prime Sciences receive?

FDA asked Prime Sciences for a written response within fifteen working days of receipt. FDA requested specific corrective steps in that response.

What corrective information did FDA request from Gram Peptides?

FDA asked Gram Peptides to detail each step taken to prevent recurrence. FDA also requested copies of related documentation.

What verification supports an FDA warning-letter close-out?

FDA verifies completed corrective actions before issuing a warning-letter close-out. Follow-up inspections usually provide that verification.

Educational and legal disclaimer

This article is for education only. For legal or medical advice, consult a qualified professional. It gives no human use guide. Ask qualified counsel to review the exact facts and current primary sources.

Sources

1. FDA warning letter to Prime Sciences, reference 721805, dated March 31, 2026, accessed August 4, 2026.

2. FDA warning letter to Gram Peptides, reference 721806, dated March 31, 2026, accessed August 4, 2026.

3. FDA warning letter to Wholesale Peptide, reference 729447, dated June 17, 2026, accessed August 4, 2026.

4. FDA, About Warning and Close-Out Letters, accessed September 25, 2026.

5. FDA, Warning Letters, accessed September 25, 2026.